Page 18 of 31: studies 171 to 180 of 305, newest first. Back to the psilocybin for anxiety overview
Zeitschrift für Phytotherapie August 1, 2022
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.1056/ NEJMoa2032994
Journal of Palliative Medicine August 1, 2022 William E Rosa, Zachary Sager, Megan Miller et al. 49 citations
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within...
Frontiers in Psychiatry July 7, 2022 Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al. 24 citations
Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in deficient treatment responses. Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy and clinical populations. The main...
Frontiers in Pharmacology June 28, 2022 Nataliya S. Vorobyeva, Alena A. Kozlova 16 citations
Classical psychedelics represent a family of psychoactive substances with structural similarities to serotonin and affinity for serotonin receptors. A growing number of studies have found that psychedelics can be effective in treating various psychiatric conditions, including post-traumatic stress disorder, major depressive disorder, anxiety, and substance use disorders. Mental health disorders...
Journal of Psychedelic Studies June 9, 2022 Annie M. Mccartney, Hugh McGovern, Alexander de Foe 8 citations
Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state...
Neuroscience & Biobehavioral Reviews June 6, 2022 Corinna L. Felsch, Kim P. C. Kuypers 23 citations
BACKGROUND: Current first-line treatment for social anxiety disorder (SAD), one of the most prevalent anxiety disorders, is limited in its efficacy. Hence, novel treatment approaches are urgently needed. The current review suggests a combination of meditation-based interventions and the administration of a psychedelic as a future alternative treatment approach. While both separate treatments...
European Psychiatry June 1, 2022 L. Silva, L. Bravo
Introduction Ayahuasca is an hallucinogenic tea prepared from the Amazonian vine Banisteriopsis caapi and the leaves of the plant Psychotria Viridis. Banisteriopsis caapi contains monoamine oxidase inhibitors (MAO) that render the N, N-dimethyltryptamine (DMT) of Psychotria Viridis active. This brew is being used as a sacrament in syncretic religions in urban areas of Brazil and worldwide with...
SURG Journal June 1, 2022 Anthony Principe 1 citation
This review presents a general background of psilocybin pharmacology and discusses its uses in treating various mental health disorders such as depression, anxiety, obsessive-compulsive disorder, and addiction. A summary of preliminary clinical trials utilizing psilocybin in each disorder is presented, along with an analysis of the neurobiological mechanisms that could explain the results. The...
Journal of Clinical Oncology June 1, 2022 Manish Agrawal, Paul Thambi, Sarah Shnayder 3 citations
12097 Background: More than 17 million people in the U.S. live with cancer and up to 25% of them have major depression. Depression leads to lower treatment adherence, reduced quality of life, and higher rates of mortality in cancer. Yet, interventions used to treat depression in patients with cancer have limited success. Prior trials using psilocybin to treat anxiety and depression associated...
Cureus May 27, 2022 Robert Sotille, Herpreet Singh, Anne Weisman et al. 2 citations
Current medications have not been effective in reducing the prevalence of mental illness worldwide. The prevalence of illnesses such as treatment-resistant depression has increased despite the widespread use of a broad set of psychopharmaceuticals. Transcranial magnetic stimulation and ketamine therapy are making great strides in improving treatment-resistant depression outcomes but they have...